A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours
YJ Kang, S O'Haire, F Franchini, M IJzerman… - Scientific reports, 2022 - nature.com
Immune checkpoint inhibitors have been approved in the USA for tumours exhibiting
mismatch repair deficiency (dMMR), microsatellite instability (MSI), or high tumour …
mismatch repair deficiency (dMMR), microsatellite instability (MSI), or high tumour …
Atezolizumab as the first systemic therapy approved for alveolar soft part sarcoma
EJ Bergsma, M Elgawly, D Mancuso… - Annals of …, 2024 - journals.sagepub.com
Objective The objective was to review the pharmacology, efficacy, and safety of
atezolizumab (Tecentriq) for the treatment of adult and pediatric patients aged 2 years and …
atezolizumab (Tecentriq) for the treatment of adult and pediatric patients aged 2 years and …
Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study
CF Friedman, JD Hainsworth, R Kurzrock, DR Spigel… - Cancer discovery, 2022 - AACR
High tumor mutational burden (TMB-H) correlates with improved immunotherapy response.
We assessed atezolizumab 1,200 mg every 3 weeks for TMB-H tumors from MyPathway …
We assessed atezolizumab 1,200 mg every 3 weeks for TMB-H tumors from MyPathway …
In Silico Re‐Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure–Response Simulation
Atezolizumab, a humanized monoclonal antibody against programmed cell death ligand 1
(PD‐L1), was initially approved in 2016, around the same time that the sponsor published …
(PD‐L1), was initially approved in 2016, around the same time that the sponsor published …
Atezolizumab and bevacizumab in patients with unresectable hepatocellular carcinoma: pharmacokinetic and safety assessments based on hepatic impairment status …
CS Shemesh, P Chan, H Shao, DZ Xu, D Combs… - Liver Cancer, 2021 - karger.com
Introduction: Phase 1b GO30140 and phase 3 IMbrave150 studies evaluated first-line
atezolizumab+ bevacizumab for unresectable hepatocellular carcinoma (HCC). Here, we …
atezolizumab+ bevacizumab for unresectable hepatocellular carcinoma (HCC). Here, we …
Targeted therapies in bladder cancer: signaling pathways, applications, and challenges
M Peng, X Chu, Y Peng, D Li, Z Zhang, W Wang… - MedComm, 2023 - Wiley Online Library
Bladder cancer (BC) is one of the most prevalent malignancies in men. Understanding
molecular characteristics via studying signaling pathways has made tremendous …
molecular characteristics via studying signaling pathways has made tremendous …
A comparison of data visualization tools: A case study in health-related research
H Huang, S Ravi, T Warrington, H Cui… - Information …, 2024 - journals.sagepub.com
Data visualization tools are important tools for making health decisions based on large
amounts of data. However, very few comparisons of data visualization tools have been done …
amounts of data. However, very few comparisons of data visualization tools have been done …
Are You a TMBeliever? Mutations and Atezolizumab Response in Solid Tumors
SB Maron, SJ Klempner - Cancer Discovery, 2022 - AACR
Optimizing the utility of tumor mutational burden in solid tumors remains an unmet need and
a clinical knowledge gap. Using a centrally determined cutoff of≥ 16 mut/Mb, Friedman and …
a clinical knowledge gap. Using a centrally determined cutoff of≥ 16 mut/Mb, Friedman and …
Recent update of PD-L1 inhibitor therapy and companion diagnostics
B Jiang - … Conference on Biological Engineering and Medical …, 2023 - spiedigitallibrary.org
PD1/PD-L1 is a suppressive pathway of immune response which can be exploited by
cancers and cause immune evasion. PD-L1 inhibitors are developed to block PD1/PD-L1 …
cancers and cause immune evasion. PD-L1 inhibitors are developed to block PD1/PD-L1 …